Drug Trial News

RSS

FDA allows Scioderm’s SD-101 IND application for Epidermolysis Bullosa to proceed

Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed. SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB).

14 Feb 2013

CATT study clarifies value of genetic testing for age-related macular degeneration

New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis- and Avastin-, the two medications most widely used to treat the "wet" form of AMD.

13 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013

Platelet-rich plasma holds great promise in treating knee OA

A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.

13 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

New medication could help patients with renal tumours triggered by tuberous sclerosis

In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).

13 Feb 2013

Preemptive treatment effective for hyperemesis gravidarum and severe morning sickness

`In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, California, researchers will present data showing the effectiveness of preemptive treatment for hyperemesis gravidarum and severe morning sickness.

13 Feb 2013

Study: 17P not effective in preventing preterm birth among women with twin pregnancies

In a study to be presented on February 14 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's 33rd annual meeting, The Pregnancy Meeting -, researchers will report findings that suggest that 17P, a form of progesterone, is not effective in preventing preterm birth among women with twin pregnancies - and may possibly be harmful.

13 Feb 2013

RNAi effective in treating cancer patients

The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.

13 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

A stroke survivor's chances of living independently after 90 days are not improved by the use of devices inserted into the artery to dissolve or remove a stroke-causing clot shortly after the onset of symptoms, according to a randomized controlled trial involving 656 patients.

11 Feb 2013

RNL BIO files new stem cell drug IND with KFDA to initiate phase II and III cerebral palsy trials

RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III assessing the company's RNL-Astrostem stem cell drug in patients with cerebral palsy.

11 Feb 2013

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans.

10 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

New insights on role of placebo in depression

A randomized controlled trial published in one of the last issue of Psychotherapy and Psychosomatics unravels new insights on the role of placebo in depression.

10 Feb 2013

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

Drug Trial News

FDA allows Scioderm’s SD-101 IND application for Epidermolysis Bullosa to proceed

CATT study clarifies value of genetic testing for age-related macular degeneration

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Tivozanib overall survival results announced by AVEO and Astellas

Platelet-rich plasma holds great promise in treating knee OA

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

New medication could help patients with renal tumours triggered by tuberous sclerosis

Preemptive treatment effective for hyperemesis gravidarum and severe morning sickness

Study: 17P not effective in preventing preterm birth among women with twin pregnancies

RNAi effective in treating cancer patients

LASAG trial for severe influenza initiated

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

RNL BIO files new stem cell drug IND with KFDA to initiate phase II and III cerebral palsy trials

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib shows promise against metastatic renal cell carcinoma

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

New insights on role of placebo in depression

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News